J&J says IMAAVY shows sustained disease control through two years in adolescent myasthenia gravis study

By Public Technologies
  • Johnson & Johnson announced new long-term data on IMAAVY for generalized myasthenia gravis, scheduled for presentation at AANEM 2026.
  • A Phase 2/3 adolescent extension study showed disease control and functional improvement held up through two years, with some steroid reduction.
  • A retrospective survey of adult treatment switches found inconsistent symptom control was the top reason to stop prior advanced therapy.
  • Clinicians reported most patients improved after moving to IMAAVY, with many also cutting prednisone use.
  • IMAAVY is positioned as an FcRn blocker with pediatric authorization in the U.S. and Europe for certain antibody-positive gMG patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609290803PR_NEWS_USPR_____NY58035) on September 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.